Trial Profile

Treosulfan-based conditioning and Rapamycin-base GvHD prophylaxis prior to un-manipulated allogeneic haematopoietic stem cell transplantation from a mismatched donor in patients with high risk haematological malignancies.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Dec 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sirolimus (Primary) ; Antithymocyte globulin; Fludarabine; Mycophenolic acid; Rituximab; Treosulfan
Indications Acute myeloid leukaemia; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Follicular lymphoma; Graft-versus-host disease; Hodgkin's disease; Mantle-cell lymphoma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma; Transplant rejection
Focus Adverse reactions
Acronyms TrRaMM

05 Jan 2013 Planned number of patients changed from 45 to 85 as reported by European Clinical Trials Database record.
26 Aug 2011 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com